Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

2023 Data Readouts Enable New Treatment Avenues in Oncogene-Driven NSCLC

February 7th 2024

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment

February 6th 2024

Coral Olazagasti, MD, discusses her participation in a case-based discussion at the 21st Annual Winter Lung Cancer Conference®.

Dr Rosner on Personalizing Approaches to Perioperative Therapy in NSCLC

February 6th 2024

Samuel Rosner, MD, discusses ongoing efforts to individualize the use of perioperative/neoadjuvant therapy in early-stage NSCLC.

EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

February 6th 2024

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Diving Into Adjuvant Approaches in Early-Stage Resectable NSCLC: PD-L1 Expression and Genomic Considerations

February 6th 2024

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Sacituzumab Govitecan + Pembrolizumab in First-Line Metastatic NSCLC

February 6th 2024

Dr. Shirish Gadgeel discusses recent EVOKE-2 trial results showing promising response rates with sacituzumab govitecan combined with pembrolizumab for metastatic non-small cell lung cancer.

The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster

February 6th 2024

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.

Santos Breaks Down Key Updates From 2023 in the Management of EGFR-Mutant NSCLC

February 6th 2024

Edgardo S. Santos Castillero, MD, FACP, expands on outcomes from pivotal phase 3 trials such as ADAURA and FLAURA2 in patients with EGFR-mutant NSCLC.

FDA Grants Fast Track Designation to UV1 Cancer Vaccine for Unresectable/Metastatic Mesothelioma

February 5th 2024

The UV1 cancer vaccine received fast track designation for use in combination with ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma.

Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC

February 4th 2024

Balazs Halmos, MD, discusses treatment strategies for patients with EGFR-mutant non–small cell lung cancer.

Dr Curran on Developing Strategies for Stage III NSCLC Management

February 4th 2024

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer.

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

February 3rd 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

State of the Science Summit - Lung Cancer: Chaired by Jobelle Baldonado, MD, and Jhanelle Gray, MD

February 1st 2024

State of the Science Summit - Lung Cancer: Chaired by Jobelle Baldonado, MD, and Jhanelle Gray, MD

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

January 31st 2024

State of Science Summit - Lung Cancer: Chaired by Shetal Patel, MD, PhD

FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC

January 31st 2024

The FDA granted priority review to a sNDA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC.

Biomarker Identification Drives Research and Drug Development in NSCLC and SCLC

January 29th 2024

Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.

Future Perspectives on the Treatment of NSCLC

January 26th 2024

Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.